Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology

Journal of Controlled Release : Official Journal of the Controlled Release Society
Omar S SakrGerrit Borchard

Abstract

Transarterial chemoembolization (TACE) is used to treat various types of hypervascular tumors such as hepatocellular carcinoma and renal cancer. However, embolization and blocking of blood vessels nourishing a tumor mass evokes an angiogenic response due to the secretion of vascular endothelial growth factor (VEGF), which results in the formation of new blood vessels and eventually limitation in therapeutic efficacy. The presented work investigates the feasibility of loading the clinically used embolic beads (DC Bead®) with Bevacizumab (BEV), an anti-VEGF antibody, and control its release kinetics via Layer-by-Layer (LbL) coating. This strategy has the aim to achieve high, localized and sustained concentrations of BEV at the tumor site and reduce drug exposure in the systemic circulation. High loading of BEV on lyophilized beads of about 76mg BEV/bead vial was achieved. LbL coating was carried out by depositing alternating layers of the biocompatible polymers alginate and poly-L-lysine. Coating was proven successful by monitoring the reversal of zeta potential after addition of each layer. Morphological changes of the bead surface before and after coating were illustrated using SEM imaging. Moreover, release profiles from diffe...Continue Reading

References

Jul 18, 2001·Journal of the American Chemical Society·S T DubasJ B Schlenoff
Dec 7, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sha LiXin-pu Hou
Apr 28, 2004·Biomaterials·Alexander SchwarzJean Raymond
Feb 9, 2005·Langmuir : the ACS Journal of Surfaces and Colloids·Kris C WoodPaula T Hammond
Mar 4, 2005·Langmuir : the ACS Journal of Surfaces and Colloids·Ludovic RichertCatherine Picart
Apr 2, 2005·Nature Reviews. Drug Discovery·Sven Frokjaer, Daniel E Otzen
Jun 21, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Shiqu YeZhen Tong
Mar 7, 2006·Journal of Vascular and Interventional Radiology : JVIR·Andrew L LewisPeter W Stratford
Oct 20, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Xiaohua LiuLai Wah Chan
Aug 28, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Y TangP W Stratford
Jan 30, 2008·Cardiovascular and Interventional Radiology·Joachim KettenbachThomas Rand
Oct 18, 2008·Expert Review of Anticancer Therapy·Maria PleguezueloAndrew K Burroughs
Nov 20, 2008·JAMA : the Journal of the American Medical Association·Shobha Rani NalluriShenhong Wu
Nov 13, 2009·Cardiovascular and Interventional Radiology·Johannes LammerUNKNOWN PRECISION V Investigators
Jan 13, 2011·Expert Opinion on Drug Delivery·Andrew L Lewis, Rachel R Holden
Feb 3, 2011·JAMA : the Journal of the American Medical Association·Vishal RanpuraShenhong Wu
Oct 20, 2011·Cardiovascular and Interventional Radiology·Riccardo LencioniJean-Francois H Geschwind
Nov 30, 2011·Progress in Polymer Science·Kuen Yong Lee, David J Mooney

❮ Previous
Next ❯

Citations

Jul 21, 2017·Advanced Healthcare Materials·Michael MöhwaldMarc Schneider
Jan 16, 2021·Drug Delivery and Translational Research·David S MonahanAamir Hameed
Jan 23, 2021·Expert Opinion on Drug Delivery·Andrew S MikhailBradford J Wood
Aug 10, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xihan LiXiaoping Zou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.